Melanoma, a malignancy of melanocytes, is a genetically diverse tumor influenced by UV exposure and other mutational drivers. This blog explores the molecular genetics, subtypes, and clinical implications of melanoma, alongside histological and pathway-focused tables.
Answer these MCQs before moving on
Video explanation
Types of Melanoma Based on UV Damage
1. High-CSD Melanoma (Cumulative Sun Damage)
High-CSD melanomas arise in chronically sun-exposed areas and exhibit features of accumulated UV damage. Key subtypes include:
- Lentigo Maligna Melanoma
- High-CSD Nodular Melanoma
- Desmoplastic Melanoma
2. Low-CSD Melanoma (Minimal UV Damage)
Low-CSD melanomas, such as Superficial Spreading Melanoma, are linked to intermittent sun exposure, often on less chronically exposed areas.
3. No-CSD Melanoma (Sun-Shielded Sites)
These melanomas occur on areas shielded from UV radiation. Key examples include:
- Mucosal Melanoma
- Acral Melanoma
- Melanomas arising in congenital or blue nevi
- Uveal Melanoma
Types of Melanoma Based on UV Damage
Table 1: Melanoma Types Based on UV Damage
| Type of Melanoma | UV Exposure | Subtypes | Key Features |
|---|---|---|---|
| High-CSD Melanoma | Chronic Sun Damage | Lentigo Maligna Melanoma, High-CSD Nodular Melanoma, Desmoplastic Melanoma | Occurs in areas with chronic UV exposure, high tumor mutational burden (TMB). |
| Low-CSD Melanoma | Intermittent Sun Damage | Superficial Spreading Melanoma | Linked to intermittent sun exposure, moderate TMB. |
| No-CSD Melanoma | None (Sun-Shielded Sites) | Mucosal Melanoma, Acral Melanoma, Malignant Spitz Tumor, Uveal Melanoma | Low TMB, associated with congenital or site-specific genetic mutations. |
Molecular Genetics of Melanoma
MAPK Pathway and Driver Mutations
Melanomas frequently harbor mutations in the MAPK signaling pathway, which drives cellular proliferation:
- BRAF Mutations (~50%): Predominantly V600E mutation, targeted by inhibitors like vemurafenib.
- NRAS Mutations (~25%): Linked to aggressive tumor behavior.
- KIT Mutations (~2%): Found in acral and mucosal melanomas.
Uveal Melanoma
This unique melanoma subtype is driven by mutations in:
- GNAQ and GNA11: These mutations activate G-protein signaling, leading to proliferation.
- BAP1: Loss of this tumor suppressor gene is associated with metastasis, particularly to the liver.
Sun Exposure and Tumor Mutational Burden (TMB)
The degree of UV damage correlates with the tumor mutational burden:
- High-CSD Melanomas: Exhibit high TMB, reflecting chronic UV-induced DNA damage.
- No-CSD Melanomas: Have very low TMB and are driven by other genetic events, such as congenital mutations.
Molecular Genetics of Melanoma
Table 2: Genetic Mutations in Melanoma by Site
| Site | Key Genetic Mutations | Associated Features |
|---|---|---|
| Cutaneous | BRAF (~50%), NRAS (~25%), KIT (~2%) | MAPK pathway activation, targeted therapies like BRAF inhibitors. |
| Mucosal | KIT mutations, NRAS mutations | Rare, occurs in sun-shielded areas, aggressive behavior. |
| Acral | KIT mutations, NRAS mutations | Found on palms, soles, and under nails, not UV-related. |
| Uveal | GNAQ, GNA11 (>90%), BAP1 loss | Distinct pathway, high metastatic potential, liver metastasis common. |
| Congenital Nevi | NRAS mutations, occasional BRAF mutations | Present at birth, may transform into melanoma. |
| Blue Nevi | GNAQ, GNA11 | Low-risk, can progress to melanoma in rare cases. |
Clinical Relevance and Therapeutic Implications
Understanding melanoma’s molecular genetics has revolutionized its diagnosis and treatment:
- Targeted Therapy: BRAF and MEK inhibitors provide precision treatment for patients with BRAF mutations.
- Immunotherapy: High mutational burden in UV-damaged melanomas makes them suitable candidates for immune checkpoint inhibitors.
- Prognostic Insights: NRAS-mutated melanomas have a poorer prognosis compared to BRAF-mutated melanomas.
Table 3: Precursor Lesions of Melanoma and Their Respective Mutations
| Precursor Lesion | Associated Melanoma Type | Common Genetic Mutations | Key Features |
|---|---|---|---|
| Congenital Nevus | Melanoma arising in congenital nevus | NRAS (~80%), occasional BRAF | Present at birth; larger lesions have a higher risk of melanoma transformation. |
| Dysplastic Nevus | Superficial Spreading Melanoma | BRAF (~50%), NRAS (~25%) | Atypical nevus with architectural disorder; often associated with familial melanoma syndromes. |
| Blue Nevus | Melanoma arising in blue nevus | GNAQ, GNA11 | Heavily pigmented, spindle-shaped melanocytes; rarely transforms into melanoma. |
| Atypical Spitz Tumor (Spitz Nevus) | Malignant Spitz Tumor | HRAS, rare BRAF or TERT promoter | Spitzoid melanocytes with atypia; rare progression to melanoma. |
| Nevus Spilus | Melanoma arising in nevus spilus | NRAS, rare BRAF | Speckled pigmented lesion; may develop melanoma within the nevus. |
Video explanation
NEET-SS Onco-pathology course
Connect with Pathology MCQs
Stay updated with the latest in pathology by following us:
References
- Robbins and Cotran Pathologic Basis of Disease (10th Edition) – Vinay Kumar, Abul Abbas, Jon Aster.
- Weedon’s Skin Pathology (5th Edition) – David Weedon.
- Diagnostic Histopathology of Tumors (5th Edition) – Christopher Fletcher.
- Molecular Pathology of Melanoma (Springer Series) – Klaus Busam.
- Pathology of Melanocytic Tumors (2nd Edition) – Raymond Barnhill.
Disclaimer: This blog is a simplified educational guide.
Leave a Reply